Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 11 recruiting now early-phase tilt

Alcoholism: early-phase trial registry

11 of 67 indexed Alcoholism trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #208 of 28,707 conditions by registered trial count.

67 US clinical trials · 11 currently recruiting · #208 of 28,707 conditions by registered trial count

Alcoholism: 67 US clinical trials tracked, 11 recruiting.

Alcoholism is the subject of 67 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 14 are in Phase 3-4 (later-stage) and 26 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute on Alcohol Abuse and Alcoholism (NIAAA), running 11 of these trials.

Enrollment posture brief

Registry condition alcoholism

OPEN 11 | RECR 16% | LATE 14 | EARLY 26 | RANK #208 | SPON 11

Nearest open-share peer: Stage IVA Lung Cancer AJCC v8 (16% recruiting · 37 trials)

Brain Metastases60.3%Ischemic Stroke44.8%Parenting40.3%Alcoholism (this)16%Acne Vulgaris2.9%
Open-enrollment share among volume-matched conditions near Alcoholism

Alcoholism lists 11 open slots (16% of 67 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Alcoholism on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Alcoholism is recruiting below its size-band peers.

    11 of 67 indexed trials (16.4%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Alcoholism research.

    National Institute on Alcohol Abuse and Alcoholism (NIAAA) accounts for 11 of 67 trials (16.4%). 34 distinct sponsors appear on at least one study for this condition label.

  3. Typical Alcoholism enrolment sits around 120 participants.

    Median target enrolment is 120 among the 66 trials that report a genuine target (sentinel values excluded). 30 of those (45.5%) plan for fewer than 100 participants.

  4. Alcoholism research is mostly interventional.

    56 interventional and 11 observational studies make up this index (83.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 110Phase 216Phase 33Phase 411

Open and recent trials

67 total, page 1 of 2

RECRUITING 10,000 participants

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

National Institute on Drug Abuse (NIDA)

NCT06676059

RECRUITING 1,000 participants

Characterization Imaging Instruments in Alcoholics and Non-Alcoholics

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT02108080

RECRUITING NA 400 participants

Behavioral and Functional Task Development, Implementation, and Testing

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT02108054

RECRUITING 240 participants

Alcohol and the Social Brain: an Alcohol-Administration Hyperscanning Study

University of Illinois at Urbana-Champaign

NCT06687525

RECRUITING NA 200 participants

Alcohol and the Social Brain: An Alcohol-Administration Hyperscanning Study Employing a Within-Subject Design

University of Illinois at Urbana-Champaign

NCT07125534

RECRUITING NA 195 participants

CRP and S&A for Inpatient Veterans

VA Office of Research and Development

NCT05054738

RECRUITING NA 186 participants

Safety and Effectiveness of the BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) for Treatment of Alcohol Use Disorder (AUD)

Brainsway

NCT07216872

RECRUITING NA 130 participants

Suicidal Behavior in Patients Diagnosed With Bipolar Disorder

Emory University

NCT02604277

RECRUITING Phase 4 60 participants

Naltrexone in AUD Reward Drinkers

University of Pennsylvania

NCT05028062

RECRUITING Phase 2 60 participants

Ketamine Alcohol (in Treatment-Resistant Depression)

Mark Niciu

NCT02122562

RECRUITING NA 40 participants

Developing Functional Connectivity-Guided TMS for Alcohol Use Disorder

VA Palo Alto Health Care System

NCT06415721

ACTIVE NOT RECRUITING NA 800 participants

Chicago Social Drinking Project

University of Chicago

NCT00961792

ACTIVE NOT RECRUITING Early Phase 1 782 participants

Behavioral Alcohol Responses (BAR) Study

Carnegie Mellon University

NCT03467191

ACTIVE NOT RECRUITING NA 234 participants

Stand Down-Think Before You Drink: An RCT of a Mobile App for Hazardous Drinking With Peer Phone Support

VA Office of Research and Development

NCT05473598

ACTIVE NOT RECRUITING NA 135 participants

Telehealth Treatment for Alcohol Use Disorder

Ria Health

NCT05747703

ACTIVE NOT RECRUITING Phase 2 50 participants

Ibudilast for Treating Alcohol Use Disorder

University of Pennsylvania

NCT05414240

COMPLETED NA 1,767 participants

Ultra-brief Intervention for Problem Drinkers

Centre for Addiction and Mental Health

NCT00688584

COMPLETED Phase 3 1,375 participants

COMBINE (Acamprosate/Naltrexone)

University of North Carolina, Chapel Hill

NCT00006206

COMPLETED 1,194 participants

The Effect of Positive and Negative Emotions on Brain Activity in Alcoholics and Nonalcoholics

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT00001675

COMPLETED 485 participants

Acamprosate: Genes Associated With Response

Mayo Clinic

NCT00662571

COMPLETED Phase 2 360 participants

Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT00027079

COMPLETED Phase 2 320 participants

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

University of Pennsylvania

NCT02371889

COMPLETED NA 319 participants

Integrated Stepped Care for Unhealthy Alcohol Use in HIV

Yale University

NCT01410123

COMPLETED Phase 4 302 participants

Managing Alcoholism in People Who Do Not Respond to Naltrexone

University of Pennsylvania

NCT00115037

COMPLETED Phase 2 208 participants

Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1

University of Pennsylvania

NCT00142844

COMPLETED Phase 2 198 participants

Drug Therapy for Alcohol Dependence in Alaska Natives (Naltrexone/Sertraline)

Yale University

NCT00000451

COMPLETED Phase 4 180 participants

Naltrexone, Craving, and Drinking

Brown University

NCT00006203

COMPLETED NA 173 participants

Individualized Assessment and Treatment for Alcoholism II

UConn Health

NCT03233802

COMPLETED Phase 2 170 participants

Topiramate for Alcohol and Cocaine Dependence

Kyle Kampman

NCT00167245

COMPLETED Phase 2 168 participants

Integrated Alcohol Disorder and PTSD Treatment

VA Office of Research and Development

NCT01601067

COMPLETED NA 164 participants

Adaptive Interventions for Problem Drinkers

Northwell Health

NCT02511808

COMPLETED Phase 4 160 participants

Post-Treatment Effects of Naltrexone

Indiana University

NCT00006449

COMPLETED Phase 2 150 participants

Gabapentin Treatment of Alcohol Dependence

The Scripps Research Institute

NCT00391716

COMPLETED Phase 4 140 participants

Naltrexone for Heavy Drinking in Young Adults

Yale University

NCT00568958

COMPLETED Phase 2 136 participants

Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients

Yale University

NCT00342563

COMPLETED Phase 4 134 participants

Sertraline Pharmacotherapy for Alcoholism Subtypes

UConn Health

NCT00368550

COMPLETED 120 participants

Chronic Alcohol and Brain Stress Circuit Response

Yale University

NCT01031264

COMPLETED Phase 4 106 participants

Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT00006204

COMPLETED Phase 2 103 participants

Mifepristone Treatment of Alcohol Use Disorder

The Scripps Research Institute

NCT02179749

COMPLETED 101 participants

Imaging Cannabinoid CB1 Receptors in Alcohol Dependence

National Institute of Mental Health (NIMH)

NCT00816439

COMPLETED Phase 4 90 participants

Naltrexone Treatment of Alcohol Abuse in Schizophrenia

State University of New York - Upstate Medical University

NCT00145847

COMPLETED Early Phase 1 88 participants

The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD

University of California, San Francisco

NCT02469259

COMPLETED Phase 2 88 participants

A Study of LY2940094 in Participants With Alcohol Dependency

BlackThorn Therapeutics

NCT01798303

COMPLETED Phase 1 79 participants

Matching Genotypes and Serotonergic Medications for Alcoholism

Brown University

NCT01113164

COMPLETED Phase 3 75 participants

Aripiprazole for Bipolar Disorder and Alcohol Use Disorder

University of Texas Southwestern Medical Center

NCT02918370

COMPLETED NA 73 participants

GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence

Yale University

NCT00611767

COMPLETED Phase 1 70 participants

Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment

University of Wisconsin, Madison

NCT02966340

COMPLETED 70 participants

The Stress-Hormone System in Alcohol-Dependent Subjects

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT00536146

COMPLETED Early Phase 1 70 participants

The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT00667771

COMPLETED Phase 2 66 participants

Effect of LY686017 on Alcohol Craving

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NCT00310427

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 16
Phase 3 3
Phase 4 11

Named interventions

Most-linked intervention names on Alcoholism records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
16 trials
naltrexone (Revia) Drug
4 trials
Naltrexone Drug
4 trials
Placebo Other
4 trials
placebo Drug
3 trials
ondansetron (Zofran) Drug
2 trials
naltrexone Drug
2 trials
Brief Advice Behavioral
2 trials

US sites by state

Facility locations filed on Alcoholism trials. A trial with sites in several states counts in each.

Connecticut 13 trials
Pennsylvania 11 trials
Maryland 11 trials
California 10 trials
Texas 7 trials
New York 7 trials
Rhode Island 4 trials
Illinois 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Alcoholism page

67 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Alcoholism condition card totals 67 registered trials; most-linked intervention Placebo; top US site state Connecticut. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.